BMS signs $475m cancer immunotherapy deal with DragonflyBristol-Myers Squibb has signed an agreement worth $475 million to develop a new form of cancer immunotherapy drug Share XBMS signs $475m cancer immunotherapy deal with Dragonflyhttps://pharmaphorum.com/news/bms-signs-475m-deal-to-develop-cancer-immunotherapy-with-dragonfly/
